Athersys, Inc. (ATHXQ)

OTCMKTS · Delayed Price · Currency is USD

0.0000

0.00 (0.00%)

Mar 2, 2026, 9:30 AM EST

900.00% (1Y)

Market Cap	62.00
Revenue (ttm)	80.00K
Net Income (ttm)	-37.51M
Shares Out	61.75M
EPS (ttm)	-1.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8,779
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	52.84
RSI	47.69
Earnings Date	n/a

About Athersys

Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1995

Employees 24

Stock Exchange OTCMKTS

Ticker Symbol ATHXQ

Full Company Profile

Financial Performance

In 2022, Athersys's revenue was $5.33 million, a decrease of -3.43% compared to the previous year's $5.51 million. Losses were -$72.53 million, -16.58% less than in 2021.

Financial Statements

News

There is no news available yet.